MAPK-IN-3

• Description :

  MAPK-IN-3 (Compound 4a) is an anti-proliferative agent that shows particularly strong inhibitory effects on KYSE 30, HCT 116, and HGC 27, with IC50 values of 0.57 μM, 3.27 μM, and 2.28 μM, respectively. MAPK-IN-3 blocks the cell cycle via a p53-dependent mechanism and induces cell apoptosis through a p53-independent mechanism. MAPK-IN-3 downregulates the expression of cell cycle-related proteins like Cyclin D1 and cyclin B1, upregulates pro-apoptotic proteins such as cleaved PARP, cleaved caspase-7, and cleaved caspase-9, and reduces the expression of anti-apoptotic proteins like Bcl-2. Additionally, MAPK-IN-3 increases the intracellular level of ROS in KYSE 30 cells and upregulates the expression of members of the MAPK signaling pathway associated with ROS, such as p-ERK, p-p38 and p-JNK[1].

• CAS Number :

  [2848599-79-9]

• UNSPSC :

  12352005

• Target :

  Bcl-2 Family; Caspase; CDK; ERK; JNK; MDM-2/p53; p38 MAPK; Reactive Oxygen Species (ROS)

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mapk-in-3.html

• Smiles :

  COC1=C(C=C2OC3=C(C(O)=C(C(OCC(NO)=O)=C3)C/C=C(C)\C)C(C2=C1C/C=C(C)\C)=O)OCC(NO)=O

• Molecular Formula :

  C28H32N2O10

• Molecular Weight :

  556.56

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Caspase 7; Caspase 9